Literature DB >> 28965633

Platinum Chemotherapy Hypersensitivity: Prevalence and Management.

Iris M Otani1, Johnson Wong2, Aleena Banerji2.   

Abstract

Hypersensitivity reactions to platinum agents are common. For carboplatin and cisplatin, the first hypersensitivity reaction typically occurs around the second and third re-exposure during the second line of therapy (eighth and ninth courses overall). For oxaliplatin, the first hypersensitivity reaction can occur throughout the treatment course. Skin testing helps risk stratify patients to appropriate desensitization protocols and assess risk for breakthrough HSRs during desensitization. A risk-stratification protocol using 3 serial skin tests and desensitization protocols enables patients with platinum agent hypersensitivity to receive first-line chemotherapy treatment safely.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carboplatin; Chemotherapy allergy; Chemotherapy desensitization; Chemotherapy hypersensitivity; Cisplatin; Oxaliplatin; Platinum agent

Mesh:

Substances:

Year:  2017        PMID: 28965633     DOI: 10.1016/j.iac.2017.06.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  7 in total

Review 1.  Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.

Authors:  Faisal ALMuhizi; Leticia De Las Vecillas Sanchez; Lucy Gilbert; Ana M Copaescu; Ghislaine A C Isabwe
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 8.667

2.  Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.

Authors:  Sirinoot Palapinyo; Jettanong Klaewsongkram; Virote Sriuranpong; Nutthada Areepium
Journal:  Pharm Pract (Granada)       Date:  2022-03-31

3.  Application of the direct peptide reactivity assay (DPRA) to inorganic compounds: a case study of platinum species.

Authors:  Jocelyn D C Hemming; Mark Hosford; Martin M Shafer
Journal:  Toxicol Res (Camb)       Date:  2019-11-20       Impact factor: 3.524

Review 4.  Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

Authors:  Joana Caiado; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2021-07-07       Impact factor: 4.806

5.  Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients.

Authors:  Sherezade Moñino-Romero; Leticia de Las Vecillas; Leila A Alenazy; Marina Labella; Zsolt Szépfalusi; Edda Fiebiger; Mariana C Castells
Journal:  J Allergy Clin Immunol Pract       Date:  2020-02-04

Review 6.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871

Review 7.  Hypersensitivity Reactions to Platinum Agents and Taxanes.

Authors:  Lulu R Tsao; Fernanda D Young; Iris M Otani; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-02       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.